JP2014509655A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509655A5
JP2014509655A5 JP2014502835A JP2014502835A JP2014509655A5 JP 2014509655 A5 JP2014509655 A5 JP 2014509655A5 JP 2014502835 A JP2014502835 A JP 2014502835A JP 2014502835 A JP2014502835 A JP 2014502835A JP 2014509655 A5 JP2014509655 A5 JP 2014509655A5
Authority
JP
Japan
Prior art keywords
weight
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
diazepam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014502835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509655A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/031453 external-priority patent/WO2012135619A2/en
Publication of JP2014509655A publication Critical patent/JP2014509655A/ja
Publication of JP2014509655A5 publication Critical patent/JP2014509655A5/ja
Pending legal-status Critical Current

Links

JP2014502835A 2011-03-31 2012-03-30 鼻腔内ベンゾジアゼピン薬剤学的組成物 Pending JP2014509655A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161469940P 2011-03-31 2011-03-31
US61/469,940 2011-03-31
PCT/US2012/031453 WO2012135619A2 (en) 2011-03-31 2012-03-30 Intranasal benzodiazepine pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2014509655A JP2014509655A (ja) 2014-04-21
JP2014509655A5 true JP2014509655A5 (cg-RX-API-DMAC7.html) 2015-05-14

Family

ID=46928023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014502835A Pending JP2014509655A (ja) 2011-03-31 2012-03-30 鼻腔内ベンゾジアゼピン薬剤学的組成物

Country Status (15)

Country Link
US (3) US20120252793A1 (cg-RX-API-DMAC7.html)
EP (1) EP2691100A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014509655A (cg-RX-API-DMAC7.html)
KR (1) KR20140029426A (cg-RX-API-DMAC7.html)
CN (1) CN103619338B (cg-RX-API-DMAC7.html)
AR (1) AR085927A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012236334B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013024968A2 (cg-RX-API-DMAC7.html)
CA (1) CA2831308A1 (cg-RX-API-DMAC7.html)
MX (1) MX357800B (cg-RX-API-DMAC7.html)
PH (2) PH12013501915A1 (cg-RX-API-DMAC7.html)
RU (2) RU2018135967A (cg-RX-API-DMAC7.html)
SG (2) SG193958A1 (cg-RX-API-DMAC7.html)
TW (1) TWI601532B (cg-RX-API-DMAC7.html)
WO (1) WO2012135619A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP5929800B2 (ja) * 2012-04-03 2016-06-08 コニカミノルタ株式会社 定着液および画像形成方法
BR112019024987A2 (pt) 2017-06-02 2020-06-16 Xeris Pharmaceuticals, Inc. Formulações de fármaco de molécula pequena resistente à precipitação
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN111836615A (zh) 2018-01-05 2020-10-27 英倍尔药业股份有限公司 通过精密鼻装置的奥氮平的鼻内递送
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3102689C (en) 2018-06-04 2023-08-29 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
CN111529489A (zh) * 2020-04-17 2020-08-14 山东省药学科学院 一种含有地西泮的鼻腔喷雾剂
KR20230146513A (ko) 2020-12-04 2023-10-19 아큐티스 바이오테라퓨틱스, 인크. 항진균 특성을 갖는 국소 로플루밀라스트 제형
IL313866A (en) 2021-12-28 2024-08-01 Arcutis Biotherapeutics Inc Topical roflomilest spray foams
WO2024058848A1 (en) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004578A (en) * 1996-10-24 1999-12-21 Alza Corporation Permeation enhances for transdermal drug delivery compositions, devices and methods
DE60038738T2 (de) * 1999-07-26 2009-07-02 Sk Holdings Co., Ltd. Transnasale anticonvulsive zusammensetzungen
EP1539285B2 (en) * 2002-09-03 2011-10-12 Pharmacure Health Care AB Nasal sprays
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US7745430B2 (en) * 2006-11-15 2010-06-29 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition
JP5539875B2 (ja) * 2007-08-31 2014-07-02 アルキメデス・デベロップメント・リミテッド 非水性医薬組成物
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
ES2440068T3 (es) * 2009-09-16 2014-01-27 Allergan, Inc. Compuestos para su uso en el tratamiento de trastornos convulsivos

Similar Documents

Publication Publication Date Title
JP2014509655A5 (cg-RX-API-DMAC7.html)
RU2018135967A (ru) Интраназальные фармацевтические композиции на основе бензодиазепина
WO2009139589A3 (en) Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
EP2827868A4 (en) PHARMACEUTICAL COMPOSITIONS WITH FATTY ACID ESTERS
AR109789A2 (es) Compuestos lipídicos
EP2598148A4 (en) PHARMACEUTICAL COMPOSITIONS WITH PEMETREXED WITH EXTENDED STORAGE STABILITY
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения
JP2012524771A5 (cg-RX-API-DMAC7.html)
DK4338805T3 (da) Eicosapentaensyreethylester til brug for at reducere risikoen for ikke-dødeligt myokardieinfarkt hos en patient i statinbehandling
EP2678075A4 (en) SOLID FORMS OF A PHARMACEUTICALLY ACTIVE SUBSTANCE
JP2014218522A5 (cg-RX-API-DMAC7.html)
EP2822923A4 (en) PREPARATION OF ALPHA, BETA-UNSATURATED CARBOXYLIC ACIDS AND THEIR ESTERS
EP2800563A4 (en) DPA-ENRICHED COMPOSITIONS OF MULTIPLE-UNSATURATED OMEGA-3 FATTY ACIDS IN A FREE ACID FORM
JP2011140525A5 (cg-RX-API-DMAC7.html)
PE20161373A1 (es) Composiciones de liberacion retardada de linaclotida
EP2747832A4 (en) AGGREGATE FORMULATIONS FOR DELAYED RELEASE
EP2643002A4 (en) PHARMACEUTICAL FORMULATIONS WITH CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION
HUE050830T2 (hu) Sztatinok és omega-3 zsírsavak gyógyászati kiszerelése kapszulázáshoz
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201100863A1 (ru) Фармацевтическая композиция, включающая диклофенак и сложный эфир гидроксижирной кислоты и полиоксиалкилена
EP2725016A4 (en) HETEROCYCLIC CARBOXYLIC ESTER DERIVATIVE
FR3015260B1 (fr) Composition anhydre anti-transpirante sous forme d'aerosol comprenant un actif anti-transpirant et un polymere ethylenique filmogene non hydrosoluble et sequence
FR2981572B1 (fr) Compositions pharmaceutiques d'acide ursodesoxycholique
EA201490222A1 (ru) Комбинированные составы на основе дарунавира
EP2827867A4 (en) PHARMACEUTICAL COMPOSITIONS WITH GLYCERINESTERS